Chimeric antigen receptor-modified T cell therapy in chronic lymphocytic leukemia
Abstract Chronic lymphocytic leukemia (CLL), a common type of B cell chronic lymphoproliferative disorder in adults, has witnessed enormous development in its treatment in recent years. New drugs such as ibrutinib, idelalisib, and venetoclax have achieved great success in treating relapsed and refra...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-11-01
|
Series: | Journal of Hematology & Oncology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13045-018-0676-3 |
id |
doaj-97426f185bf449538e8ad72bd70a7828 |
---|---|
record_format |
Article |
spelling |
doaj-97426f185bf449538e8ad72bd70a78282020-11-25T02:17:19ZengBMCJournal of Hematology & Oncology1756-87222018-11-0111111210.1186/s13045-018-0676-3Chimeric antigen receptor-modified T cell therapy in chronic lymphocytic leukemiaYixin Zou0Wei Xu1Jianyong Li2Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province HospitalDepartment of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province HospitalDepartment of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province HospitalAbstract Chronic lymphocytic leukemia (CLL), a common type of B cell chronic lymphoproliferative disorder in adults, has witnessed enormous development in its treatment in recent years. New drugs such as ibrutinib, idelalisib, and venetoclax have achieved great success in treating relapsed and refractory (R/R) CLL. In addition, with the development of immunotherapy, chimeric antigen receptor-engineered T cells (CAR-T) therapy, a novel adoptive immune treatment, has also become more and more important in treating R/R CLL. It combines the advantages of T cells and B cells via ex vivo gene transfer technology and is able to bind targets recognized by specific antibodies without antigen presentation, thus breaking the restriction of major histocompatibility complex. So far, there have been lots of studies exploring the application of CAR-T therapy in CLL. In this review, we describe the structure of chimeric antigen receptor, the preclinical, and clinical results of CAR-T therapy against CLL, along with its adverse events and advances in efficacy.http://link.springer.com/article/10.1186/s13045-018-0676-3Chimeric antigen receptorChronic lymphocytic leukemiaImmunotherapyT cellToxicity |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Yixin Zou Wei Xu Jianyong Li |
spellingShingle |
Yixin Zou Wei Xu Jianyong Li Chimeric antigen receptor-modified T cell therapy in chronic lymphocytic leukemia Journal of Hematology & Oncology Chimeric antigen receptor Chronic lymphocytic leukemia Immunotherapy T cell Toxicity |
author_facet |
Yixin Zou Wei Xu Jianyong Li |
author_sort |
Yixin Zou |
title |
Chimeric antigen receptor-modified T cell therapy in chronic lymphocytic leukemia |
title_short |
Chimeric antigen receptor-modified T cell therapy in chronic lymphocytic leukemia |
title_full |
Chimeric antigen receptor-modified T cell therapy in chronic lymphocytic leukemia |
title_fullStr |
Chimeric antigen receptor-modified T cell therapy in chronic lymphocytic leukemia |
title_full_unstemmed |
Chimeric antigen receptor-modified T cell therapy in chronic lymphocytic leukemia |
title_sort |
chimeric antigen receptor-modified t cell therapy in chronic lymphocytic leukemia |
publisher |
BMC |
series |
Journal of Hematology & Oncology |
issn |
1756-8722 |
publishDate |
2018-11-01 |
description |
Abstract Chronic lymphocytic leukemia (CLL), a common type of B cell chronic lymphoproliferative disorder in adults, has witnessed enormous development in its treatment in recent years. New drugs such as ibrutinib, idelalisib, and venetoclax have achieved great success in treating relapsed and refractory (R/R) CLL. In addition, with the development of immunotherapy, chimeric antigen receptor-engineered T cells (CAR-T) therapy, a novel adoptive immune treatment, has also become more and more important in treating R/R CLL. It combines the advantages of T cells and B cells via ex vivo gene transfer technology and is able to bind targets recognized by specific antibodies without antigen presentation, thus breaking the restriction of major histocompatibility complex. So far, there have been lots of studies exploring the application of CAR-T therapy in CLL. In this review, we describe the structure of chimeric antigen receptor, the preclinical, and clinical results of CAR-T therapy against CLL, along with its adverse events and advances in efficacy. |
topic |
Chimeric antigen receptor Chronic lymphocytic leukemia Immunotherapy T cell Toxicity |
url |
http://link.springer.com/article/10.1186/s13045-018-0676-3 |
work_keys_str_mv |
AT yixinzou chimericantigenreceptormodifiedtcelltherapyinchroniclymphocyticleukemia AT weixu chimericantigenreceptormodifiedtcelltherapyinchroniclymphocyticleukemia AT jianyongli chimericantigenreceptormodifiedtcelltherapyinchroniclymphocyticleukemia |
_version_ |
1724886996549107712 |